IADR Abstract Archives

Hypersensitivity relief of MIH affected molars using two sealing techniques

Objectives: The objective of this exploratory pilot study was to compare the efficacy in reducing hypersensitivity in Molar Incisor Hypomineralisation (MIH) affected molars immediately and over 12 weeks after sealing using two different materials (composite and glass ionomer).
Methods: 12 children with at least two MIH affected molars showing hypersensitivity and non-occlusal breakdowns were included. Hypersensitivity was assessed with an evaporative (air) stimulus. A split-mouth design was used in which the two materials (A: Clinpro Sealant in combination with Scotchbond Universal, B: Ketac Universal; 3 M) were randomly placed in MIH molars by one calibrated operator. Clinical pain assessments (Schiff Score Air Sensitivity Scale [SCASS], Visual Analog Scale [VAS]) were made before treatment (“pre”), immediately after treatment (“post”) and after one, four, eight and 12 weeks. Friedman tests for repeated measures and Mann-Whitney U tests were calculated.
Results: 24 molars with an air blast hypersensitivity score of 2 or 3 (SCASS) were included. All participants completed all stages of the study. Regardless of the material used, the application of the sealant decreased hypersensitivity significantly immediately as well as throughout the 12 weeks recalls (all p-values < 0.001). Mean SCASS and VAS scores (± standard deviation) are depicted in the table. There was no statistically significant difference among both materials chosen in any of the time points evaluated.
Conclusions: In conclusion, both materials (composite sealant and glass ionomer) were able to reduce hypersensitivity successfully during this 12-weeks trial.
IADR/AADR/CADR General Session
2019 IADR/AADR/CADR General Session (Vancouver, BC, Canada)
Vancouver, BC, Canada
2019
0741
Dental Materials 8: Clinical Trials
  • Bekes, Katrin  ( Medical University Vienna , Vienna , Austria )
  • Priller, Julia  ( Medical University Vienna , Vienna , Austria )
  • Stamm, Tanja  ( Medical University of Vienna , Vienna , Austria )
  • 3 M
    The study was funded by 3M.
    Poster Session
    Clinical Trials I
    Thursday, 06/20/2019 , 11:00AM - 12:15PM
    Table 1
     prepost1 week4 weeks8 weeks12 weeks
    SCASS      
    Clinpro2.3 (±0.5)0 (±0)0 (±0)0 (±0)0 (±0)0 (±0)
    Ketac2.2 (±0.4)0 (±0)0 (±0)0 (±0)0 (±0)0 (±0)
    VAS      
    Clinpro7.3 (±1.7)0.1 (±0.3)0.3 (±1.2)0 (±0)0 (±0)0.2 (±0.6)
    Ketac6.6 (±1.3)0.1 (±0.3)0.2 (±0.6)0 (±0)0 (±0)0 (±0)